论文部分内容阅读
目的:观察孟鲁司特联合布地奈德预防婴幼儿呼吸道合胞病毒(RSV)毛细支气管炎后喘息复发的疗效和安全性。方法:RSV毛细支气管炎患儿76例随机分为对照组与观察组。两组患儿均给予吸氧、抗病毒和止咳等常规综合治疗。对照组加用布地奈德混悬液1 ml雾化吸入,bid,症状消失后停药;观察组在对照组基础上加用孟鲁司特咀嚼片2.5 mg,qd,睡前口服,连用3个月。观察并比较两组患儿治疗后主要症状体征的消退时间和住院时间,随访观察治疗结束后3个月和6个月内喘息的复发率。结果:观察组患儿的喘憋、咳嗽和肺部喘鸣音消失时间和住院时间均明显短于对照组(P<0.05);治疗后随访观察3个月和6个月,观察组患儿的喘息的复发率均明显低于对照组(P<0.05)。结论:布地奈德联合孟鲁司特治疗RSV毛细支气管炎的疗效确切,安全性好,能明显改善患儿症状和体征,明显缩短住院时间,并能降低其喘息的复发率。
Objective: To observe the efficacy and safety of montelukast combined with budesonide in the prevention of respiratory recurrence after infantile respiratory syncytial virus (RSV) bronchiolitis. Methods: 76 children with RSV bronchiolitis were randomly divided into control group and observation group. Two groups of children were given oxygen, anti-virus and cough and other conventional comprehensive treatment. The control group plus budesonide suspension 1 ml inhalation, bid, the symptoms disappear after discontinuation; observation group in the control group based on the use of montelukast tablets chewable tablets 2.5 mg, qd, bedtime oral administration, 3 Months. The subsided time and hospital stay of the main symptoms and signs after treatment in both groups were observed and compared. The recurrence rates of wheezing within 3 months and 6 months after the end of treatment were observed. Results: The disappearing time and hospitalization time of wheezing, coughing and wheezing in the observation group were significantly shorter than those in the control group (P <0.05). The patients in the observation group were followed up for 3 months and 6 months, and the children in the observation group The recurrence rate of wheezing was significantly lower than that of the control group (P <0.05). Conclusion: Budesonide combined with montelukast in the treatment of RSV bronchiolitis is effective and safe. It can significantly improve children ’s symptoms and signs, shorten the length of hospital stay and reduce the recurrence rate of wheezing.